GreenBone Ortho
GreenBone Ortho S.p.A. is an Italian medical device company that develops and commercializes b.Bone, a CE-marked biomimetic bone graft substitute made by biomorphically transforming rattan wood into a hydroxyapatite/beta-tricalcium phosphate scaffold. It sells to orthopedic and trauma surgeons and hospitals across Italy, Germany, and Austria via distribution partners.
- Company typePrivate
- Founded2014
- HeadquartersFaenza, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GreenBone Ortho does
GreenBone Ortho S.p.A. is an Italian medical device company headquartered in Faenza with manufacturing in Roncadelle, founded in 2014-2015 to commercialize bone graft substitute technology originating from research at ISTEC-CNR (Institute of Science and Technology for Ceramics – National Research Council). The company's sole commercial product is b.Bone, a CE-marked, ISO 10993-compliant bone substitute derived from rattan wood through a patented multi-step biomorphic transformation process that converts the natural wood structure into an inorganic hydroxyapatite/beta-tricalcium phosphate scaffold. The biomimetic 3D porous architecture preserves ion-doped bone-like chemistry (CO32-, Mg2+, Sr2+) and supports osteoinductive bone regeneration, with the product offered in four form factors (cylinders, blocks, wedges, granules) for traumatology, bone augmentation, deformity correction, non-union, osteotomy, and joint revision applications.
The business model is hardware sales of b.Bone medical devices through a hybrid channel: direct field sales to orthopedic surgeons and hospitals supported by clinical evidence generation, plus regional distribution partnerships — Abiogen Pharma and Mikai in Italy, and Endocon for Germany and Austria since September 2024. The company sells to orthopedic and trauma surgeons at hospital procurement level, with its clinical value proposition positioned against autograft (eliminating donor site morbidity) and conventional synthetic bone substitutes. Revenue is not publicly disclosed. The company has raised approximately €27.5 million in equity and non-dilutive funding from META Ventures, Italian Angels for Growth, Innogest Capital, 3B Future Health Fund, CDP Venture Capital, Invitalia Ventures, the European Innovation Council, and a Regione Lombardia grant.
The company is pursuing geographic expansion (DACH, with UK clinical study activity) and indication extension, most notably via the May 2026 AstroBone experiment on the International Space Station — a partnership with ESA, ASI, San Martino Hospital, and the University of Genoa — to test b.Bone behavior in microgravity for osteoporosis treatment. Patient-specific custom-made implants are in development under the Fast-Tech grant. The company holds 11-50 employees, is privately held, and is led by CEO Saverio Gellini with a management team drawn from Medtronic, Invatec, and other medical device backgrounds.
GreenBone Ortho firmographics
Firmographics- Name
- GreenBone Ortho
- Legal name
- GREENBONE ORTHO SPA
- Website
- https://greenbone.it
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GreenBone Ortho S.p.A. is an Italian medical device company that develops and commercializes b.Bone, a CE-marked biomimetic bone graft substitute made by biomorphically transforming rattan wood into a hydroxyapatite/beta-tricalcium phosphate scaffold. It sells to orthopedic and trauma surgeons and hospitals across Italy, Germany, and Austria via distribution partners.
- Ownership category
- akta.pro rank
GreenBone Ortho industry classification
Industry- Product category
- Orthopedic Bone Regeneration Medical Devices
- NAICS
- Dental Equipment and Supplies Manufacturing (339114), Dental Laboratories (339116)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Dental Equipment & Supplies (3843)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
Keywords
Where GreenBone Ortho is headquartered
LocationHeadquarters
- HQ city
- Faenza
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
GreenBone Ortho business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- b.Bone Bone Substitute Products: GreenBone Ortho generates revenue through the sale of its b.Bone biomimetic bone substitute products, which are available in multiple forms including cylinders, blocks, wedges, and granules. The products are sold to hospitals and orthopedic surgeons for bone regeneration procedures.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
GreenBone Ortho product offering
Product offeringCore offering
GreenBone Ortho manufactures and sells b.Bone, an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. The product is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics natural human bone architecture. It is available in four form factors (cylinders, blocks, wedges, granules) for orthopedic applications including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.
Product overview
GreenBone Ortho's core offering is the b.Bone product line, a family of biomimetic bone substitute scaffolds derived from rattan wood through a proprietary multi-step biomorphic transformation process. The product portfolio includes four main form factors (cylinders, blocks, wedges, and granules) designed for various orthopedic clinical applications including traumatology, bone augmentation, correction of deformity, bone lengthening, non-union treatment, osteotomy, and joint revision. The technology transforms natural rattan wood into inorganic biomaterial while preserving its hierarchical architecture, creating scaffolds that promote new bone formation and remodeling.
Differentiator
Problem solved
Functional benefit
Brands
- b.Bone: Innovative biomimetic bone substitute product derived from rattan wood through a patented biomorphic transformation process. CE-marked medical device for bone regeneration in orthopedic procedures.
Products and services
- b.Bone Bone Substitute b.Bone is an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. It is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics the hierarchical architecture of natural human bone. Available in cylinders, blocks, wedges, and granules, it is used by orthopedic and trauma surgeons for bone regeneration procedures including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.
Quantifiable outcome
- 75% average bone healing rate at 12 months in LongBone clinical study
- +4 more outcomes
Companies that use GreenBone Ortho
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles1 record
GreenBone Ortho technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
GreenBone Ortho partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered key, foundational, project, supporting and minor.
- EndoconkeyStrategic partnership formed September 2024 to bring GreenBone's bone substitute to Germany and Austria. Endocon has deep expertise and strong network in the orthopedic sector.
- MikaikeyItalian distribution partner announced February 2024 for long-term partnership to distribute GreenBone's innovative bone substitute in the Italian market.
- Abiogen PharmakeyItalian distribution partner for b.Bone bone substitute products. Agreement signed May 2022 for distribution in Italian market. Abiogen is specialized in orthopedic and healthcare products.
- ISTEC-CNR (Institute of Science and Technology for Ceramics – National Research Council)foundationalResearch institution in Faenza, Italy where the original biomorphic transformation technology was developed by Dr. Anna Tampieri and her team. Dr. Tampieri continues as Board Member of GreenBone.
- Kayser Space (FAE Technology subsidiary)projectDesigned and built the sixteen experiment units housing b.Bone scaffold for ISS space experiment. Provided essential infrastructure for survival, growth and monitoring of mesenchymal stem cells in microgravity.
- ESA (European Space Agency)projectEuropean Space Agency partnered with GreenBone for AstroBone experiment on International Space Station to test b.Bone behavior in microgravity conditions for osteoporosis research.
- ASI (Agenzia Spaziale Italiana)projectItalian Space Agency supporting the AstroBone project alongside ESA for testing b.Bone on ISS for osteoporosis treatment validation.
- INBAR (International Bamboo and Rattan Organization)supportingIntergovernmental organization collaborating with GreenBone to promote local partnerships for rattan nursery and proprietary plantations, ensuring environmental sustainability of raw material sourcing.
- Clinica MobileminorWorldwide partnership announced February 2021 with MotoGP and SuperBike medical team, bringing GreenBone bone substitute to professional motorsport for potential orthopedic applications.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
GreenBone Ortho competitors and assessment
Company assessmentDirect peers
- Orthofix Medical: Orthofix Medical offers bone growth stimulation devices and orthobiologics (Trinity Elite allograft, FIBERGRAFT) for spine and orthopedic trauma. Closely comparable to GreenBone as a specialty orthobiologics competitor with overlapping indications and channel model.
- Curasan: Curasan is a German specialty orthobiologics company marketing synthetic bone graft substitutes (Cerasorb) for dental and orthopedic indications. European mid-cap comparable to GreenBone in size, product type, and commercialization stage.
- Bonesupport: Bonesupport is a Swedish orthobiologics company commercializing CERAMENT, an injectable bone void filler for trauma and orthopedic applications. Directly comparable to GreenBone as a European specialty bone graft substitute player with a single differentiated synthetic technology and CE-marked commercial product.
- OssDsign: OssDsign is a Swedish med-tech company developing calcium phosphate-based bone graft substitutes (OSSIX Bone, OSSA product family) for cranial and orthopedic applications. Closely comparable to GreenBone in product technology, scale, and European specialty orthobiologics positioning.
Broad incumbents
- Smith+Nephew: Smith+Nephew markets bone graft substitutes including MAGNEZIUM and HEALOS through its Orthopaedics franchise. Large incumbent with global commercial reach that overlaps with GreenBone's European trauma and reconstruction target indications.
- Stryker: Stryker's Orthopaedics and Spine segments sell Vitoss, OP-1 Putty, and other bone graft substitutes. Large incumbent with established trauma and reconstructive surgery sales channels that compete head-to-head with b.Bone in hospital procurement cycles.
- Bioventus: Bioventus is an established orthobiologics company offering bone graft substitutes (including SIGNAFUSE, OSTEOAMP) and osteoarthritis pain treatments. Broader incumbent portfolio overlapping directly with GreenBone's bone graft substitute category, with deeper commercial reach.
- MTF Biologics: MTF Biologics is a major US tissue bank providing allograft-based bone graft substitutes (including Trinity Evolution, Map3) for orthopedic and sports medicine. Competes with GreenBone in the same orthopedic indications via allograft rather than synthetic route.
- Zimmer Biomet: Zimmer Biomet offers a broad orthobiologics portfolio including CopiOs, Regenafil/Regenakit, and bone void fillers for reconstructive and trauma surgery. Competes with GreenBone for hospital formulary slots and orthopedic surgeon adoption across the same indications.
- Medtronic: Medtronic's Spine division markets Infuse (rhBMP-2) and Mastergraft synthetic bone void fillers for spinal fusion and orthopedic trauma. Largest-scale competitor in the bone graft substitute category with unmatched hospital contracts and KOL relationships.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
GreenBone Ortho social profiles
Digital presenceGreenBone Ortho compliance and trust
Trust signalCompliance2 records
GreenBone Ortho financial estimates
Financial estimateRevenue estimate
Valuation estimate
GreenBone Ortho leadership team
Management profileNumber of profiles
Profiles9 records
GreenBone Ortho funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GreenBone Ortho M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GreenBone Ortho
What does GreenBone Ortho do?
GreenBone Ortho manufactures and sells b.Bone, an innovative biomimetic and bioactive bone substitute derived from rattan wood through a proprietary biomorphic transformation process. The product is composed of hydroxyapatite and beta-tricalcium phosphate in a highly interconnected porous 3D structure that mimics natural human bone architecture. It is available in four form factors (cylinders, blocks, wedges, granules) for orthopedic applications including traumatology, bone augmentation, deformity correction, bone lengthening, non-union treatment, osteotomy, and joint revision.
Is GreenBone Ortho a public or private company?
GreenBone Ortho is a private company. It is classified as venture growth investor backed and is currently operating.
When was GreenBone Ortho founded?
GreenBone Ortho was founded in 2014. It employs 11 to 50 people.
Where is GreenBone Ortho based?
GreenBone Ortho is headquartered in Faenza, Italy, in the Europe region.
How does GreenBone Ortho make money?
One revenue line is on record: b.Bone Bone Substitute Products.
Who are GreenBone Ortho's main competitors?
Direct peers on record are Orthofix Medical, Curasan, Bonesupport and OssDsign. Broad incumbents are Smith+Nephew, Stryker, Bioventus, MTF Biologics, Zimmer Biomet and Medtronic.
Does GreenBone Ortho have an API?
No public API is recorded for GreenBone Ortho.
What industry is GreenBone Ortho in?
GreenBone Ortho's product category is Orthopedic Bone Regeneration Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339114 and its SIC code is 3842.